Form 13G LENZ Therapeutics For: 8 April
- Investing.com
- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
LENZ Therapeutics Inc (LENZ)
Assess today's live LENZ Therapeutics Inc (LENZ) share price, performance and insights using our live NASDAQ: LENZ stock exchange data.
Analyse the historical data and LENZ Therapeutics Inc share price performance charts on this page. Our technical summary section provides analysis on LENZ Therapeutics share price buy/sell indicators using real-time data (or discuss the LENZ Therapeutics (LENZ) stock price today with other investors in the LENZ Therapeutics NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ LENZ share price (ISIN: US52635N1037) to enhance your trading decisions with our free investment tools and resources.
What Is the LENZ Therapeutics Inc Share Price Today?
The LENZ Therapeutics share price today is 9.07.
What Is the Stock Symbol for LENZ Therapeutics Inc
The stock symbol (or 'ticker') for LENZ Therapeutics Inc is "LENZ."
What Stock Exchange Does LENZ Therapeutics Inc Trade On?
LENZ Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is LENZ Therapeutics Inc a Good Stock to Buy?
Determining whether LENZ Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics.
Analyse the historical data and LENZ Therapeutics Inc share price performance charts on this page. Our technical summary section provides analysis on LENZ Therapeutics share price buy/sell indicators using real-time data (or discuss the LENZ Therapeutics (LENZ) stock price today with other investors in the LENZ Therapeutics NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ LENZ share price (ISIN: US52635N1037) to enhance your trading decisions with our free investment tools and resources.
What Is the LENZ Therapeutics Inc Share Price Today?
The LENZ Therapeutics share price today is 9.07.
What Is the Stock Symbol for LENZ Therapeutics Inc
The stock symbol (or 'ticker') for LENZ Therapeutics Inc is "LENZ."
What Stock Exchange Does LENZ Therapeutics Inc Trade On?
LENZ Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is LENZ Therapeutics Inc a Good Stock to Buy?
Determining whether LENZ Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
8.99
9.33
52 wk Range
8.25
50.40
LENZ is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
8.999.33
52 wk Range
8.2550.40
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
LENZ Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
41.14
Upside
+353.61%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
- Graphite Bio receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- Form 13G LENZ Therapeutics For: 8 April
- Investing.com
- Lenz Therapeutics CFO Chevallard buys $64k in stock
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell
LENZ Therapeutics, Inc. operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include VIZZ and LNZ101 for the treatment of presbyopia in adults. LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Therapeutics, Inc. in June 2021. The company was founded in 2013 and is headquartered in Solana Beach, California.
LENZ Therapeutics Inc Earnings Call Summary for Q4/2025
- LENZ reported $1.6M Q4 revenue from VIZZ presbyopia treatment launch; holds $292.3M cash with zero debt but posted $35.9M net loss.
- Operating expenses surged 43% sequentially to $40M; net loss per share widened to $1.16 from $0.46 year-over-year in Q4.
- Stock plunged 12% post-earnings to $10.5, near 52-week low, down 73% over six months despite analyst targets of $35-$62.
- Company projects Q1 2026 VIZZ sales exceeding 45,000 boxes; plans to allocate 75-80% of expenses to sales/marketing with 90% gross margin.
- Executives emphasized strong liquidity position to fund growth while facing investor concerns over sustained losses and elevated cash burn rate.
Last Updated: 24/03/2026, 14:00
Read Full TranscriptCompare LENZ to Peers and Sector
Metrics to compare | LENZ | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipLENZPeersSector | |
|---|---|---|---|---|
P/E Ratio | −3.5x | −8.9x | −0.4x | |
PEG Ratio | 0.16 | −0.11 | 0.00 | |
Price/Book | 1.0x | 1.8x | 2.6x | |
Price / LTM Sales | 14.9x | 7.9x | 3.2x | |
Upside (Analyst Target) | 330.0% | 49.2% | 50.9% | |
Fair Value Upside | Unlock | 5.4% | 6.8% | Unlock |
Analyst Ratings
7 Buy
0 Hold
0 Sell
Ratings:
7 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 41.14
(+353.61% Upside)
Earnings
Latest Release
24/03/2026
EPS / Forecast
-1.16 / -0.76
Revenue / Forecast
1.59M / --
People Also Watch
FAQ
What Is the LENZ Therapeutics (LENZ) Share Price Today?
The LENZ Therapeutics stock price today is 9.07 USD.
What Stock Exchange Does LENZ Therapeutics (LENZ) Trade On?
LENZ Therapeutics is listed and trades on the Nasdaq Stock Exchange.
What Is the Ticker (Stock Symbol) for LENZ Therapeutics?
The stock symbol (also called a 'ticker') for LENZ Therapeutics is "LENZ."
What Is the Current LENZ Therapeutics Market Cap?
As of today, LENZ Therapeutics market cap is 284.38M USD.
What Is LENZ Therapeutics's (LENZ) Earnings Per Share (TTM)?
The LENZ Therapeutics EPS is currently -2.85 (Trailing Twelve Months).
Is LENZ a Buy or Sell From a Technical Analyst Perspective?
Based on today's LENZ Therapeutics moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has LENZ Therapeutics Stock Split?
LENZ Therapeutics has split 1 times. (See the LENZ stock split history page for full effective split date and price information.)
How Many Employees Does LENZ Therapeutics Have?
LENZ Therapeutics has 152 employees.
What is the current trading status of LENZ Therapeutics (LENZ)?
As of 11/04/2026, LENZ Therapeutics (LENZ) is trading at a price of 9.07 USD, with a previous close of 9.29 USD. The stock has fluctuated within a day range of 8.99 USD to 9.33 USD, while its 52-week range spans from 8.25 USD to 50.40 USD.
What Is LENZ Therapeutics (LENZ) Price Target According to Analysts?
The average 12-month price target for LENZ Therapeutics is 41.14 USD, with a high estimate of 60 USD and a low estimate of 20 USD. 7 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +353.61% Upside potential.
What Is the LENZ Premarket Price?
LENZ's last pre-market stock price is 9.26 USD. The pre-market share volume is 610.00, and the stock has decreased by -0.03, or -0.32%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.